Cancer and Leukemia Group B

描述（由申请人提供）：杜克医学中心作为癌症和白血病B组（CALGB）的成员，目前正在完成其第三个5年资助周期。在杜克大学参与CALGB的过程中，该机构一直是患者总收益最高的机构之一，并在2000年和2001年被公认为主要成员机构的患者收益以及不断增长的附属网络方面的领先机构。杜克大学和附属网络的大量患者的数据质量都非常好。患者资源对内部和外部合作小组活动的高水平承诺与杜克大学教师在CALGB疾病和模式委员会的高水平科学参与相匹配。擅长的领域包括乳腺癌及相关研究、老年癌症及健康结果、白血病/淋巴瘤及移植、呼吸系统癌症、胸外科及相关研究。在这些领域的试点工作已导致在当前赠款周期内在CALGB内制定整个集团范围的协议，并已为下一个研究期间制定了若干概念和建议。额外的教师招聘将进一步扩大杜克大学在CALGB中的科学影响。此外，由杜克大学教师和研究人员组成的农村肿瘤诊所的杜克肿瘤网络将增加临床试验中更多不同人群的患者的登记。杜克大学在CALGB的科学参与、患者累积和数据质量方面取得的成功源于癌症中心对临床研究和合作小组活动的长期承诺。校内和校外的临床试验参与都通过设在杜克癌症中心的集中临床试验办公室进行协调。在过去的15年里，在Jeffrey Crawford博士的指导下，组织结构得到了发展和完善，他既是CALGB活动的首席研究员，也是杜克大学综合癌症中心的临床研究主任。这一组织结构通过与CALGB生物统计和数据管理中心的密切互动得到进一步加强，该中心总部位于杜克大学，由Stephen George博士指导，他也是杜克大学癌症中心的生物统计主任。作为过去15年来CALGB活动的领先机构，杜克大学期待在下一个拨款周期中获得适合我们当前和不断增长的患者累积和科学参与CALGB试验水平的资金支持。

DESCRIPTION (provided by applicant): Duke Medical Center is currently completing its third 5-year grant cycle as a member of Cancer and Leukemia Group B (CALGB). Throughout Duke's involvement with CALGB this institution has consistently been one of the top institutions in overall patient accrual and was recognized in 2000 and 2001 as being the leading institution both in terms of patient accrual from the main member institution as well as from a growing affiliate network. Data quality for this large number of patients both at Duke and across the affiliate network has been excellent. This high level of commitment of patient resources to cooperative group activities both intramurally and extramurally is matched by a high level of scientific participation by Duke faculty across the disease and modality committees of CALGB. Particular areas of strength include Breast Cancer and Correlative Studies, Cancer in the Elderly and Health Outcome, Leukemia/Lymphoma and Transplant, and Respiratory Cancer, Thoracic Surgery, and Correlative Studies. Pilot work in these areas has led to group wide protocols within CALGB during the current grant cycle with several concepts and proposals already developed for the next study period. Additional faculty recruitment will further expand the scientific impact of Duke within CALGB. Furthermore, the Duke Oncology Network of rural oncology clinics staffed by Duke faculty and research personnel will enhance enrollment of a more diverse population of patients on clinical trials. The success that Duke has had within CALGB in terms of scientific participation, patient accrual, and data quality stem from a longstanding commitment for the Cancer Center to clinical research and cooperative group activities. Both intramural and extramural clinical trial participation is coordinated through centralized clinical trials offices, housed within the Duke Cancer Center. The organizational structure has been developed and refined over the last 15 years under the direction of Dr. Jeffrey Crawford, who serves both as the Principal Investigator for CALGB activities, as well as Director for clinical research for the Duke Comprehensive Cancer Center. This organizational structure is further strengthened by close interaction with the CALGB Biostatistics and Data Management Center, which is headquartered at Duke under the direction of Dr. Stephen George, who is also the Director of Biostatistics for the Duke Cancer Center. As a leading institution within CALGB activities over the last 15 years, Duke is looking forward to funding support appropriate to our current and growing level of patient accrual and scientific involvement in CALGB trials during the next grant cycle.